Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US7122514B2 · kind B2 · utility
12Cited by
7References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2003 |
| Grant date | Oct 17, 2006 |
| Priority date | — |
| Expiry date | Jul 23, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/24075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include β-lactams and glycopeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.